Samsung Biologics Partners with Kurma for Biologics Development and Manufacturing
Samsung Biologics will provide CMC (chemistry, manufacturing, and control) services to streamline the gene-to-IND (investigational new drug) process for Kurma Partners' portfolio companies, accelerating clinical development with its advanced facilities and expertise.
John Rim, President and CEO of Samsung Biologics commented, “With our in-depth knowledge on effective scale-up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance, and ultimately maximize manufacturing efficiency for our clients.”
“We are very excited to partner with Samsung Biologics, a world-leading CDMO with capabilities of highest industry standards. This will greatly benefit our portfolio of Kurma Biofunds and Kurma Growth Opportunities Fund in advancing large molecule biologics from discovery to the market.” said Daniel Parera, Partner at Kurma Partners.
This agreement highlights Samsung Biologics' eagerness to work with emerging biotech firms in drug development and manufacturing while expanding its presence in key sectors in the U.S. and European markets.
300 Songdo bio-daero, Yeonsu-gu
24 rue Royale, 5e etage
+33 (0)1 84 86 08 61